查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1702362

全球生物電醫學市場 - 2025-2033

Global Bioelectric Medicine Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 165 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球生物電醫療市場規模達到 313.4 億美元，預計到 2033 年將達到 2,355.5 億美元，在 2025-2033 年預測期內的複合年成長率為 22.3%。

生物電醫學，也稱為電療法，是一門利用電脈衝治療心律不整、癲癇、帕金森氏症和慢性疼痛等疾病的醫學科學。它涉及刺激特定神經或組織的植入式裝置，為神經病學、心臟病學和其他治療領域的藥物治療提供創新的替代方案。該技術整合了神經調節和生物工程，提高了患者的治療效果。

市場動態：

駕駛員和約束裝置

慢性病盛行率不斷上升

生物電醫學市場的發展受到心血管疾病、神經系統疾病和慢性疼痛等慢性疾病日益流行的推動，以及人口老化和心律不整、癲癇和帕金森氏症病例的增加，而神經調節技術的進步和電醫學應用的不斷擴大又推動了生物電醫學市場的發展。例如，國際糖尿病聯合會報告稱，2021年，全球有5.366億成年人（即十分之一的人口）患有糖尿病，預計到2030年這一數字將上升到6.428億，到2045年將上升到7.837億，尤其是在中低收入國家，這凸顯了對糖尿病護理藥物和設備的迫切需求。

因此，糖尿病盛行率的上升推動了對包括生物電醫學在內的先進治療方案的需求。生物電療法，如神經調節裝置，為控制併發症和改善患者預後提供了一個有希望的替代方法，特別是在中低收入國家。

設備相關併發症的風險

生物電醫學市場面臨挑戰，因為潛在的設備相關併發症，如感染、故障和免疫反應。植入式生物電設備需要手術操作，有術後感染、電極移位和硬體故障的風險。長期使用可能需要更換設備，增加醫療成本和患者擔憂，可能限制生物電醫學的廣泛應用。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第2章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按產品類型分類的程式碼片段
  • 按應用程式截取的程式碼片段
  • 最終用戶的程式碼片段
  • 按地區分類

第3章：動態

  • 影響因素
    • 驅動程式
      • 慢性病盛行率不斷上升
      • 科技進步的興起
    • 限制
      • 設備相關併發症的風險
      • 嚴格的監管要求和核准延遲
    • 機會
      • 研發投資增加
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的既定領導者
    • 擁有成熟產品的市場領導者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第5章：依產品類型

  • 植入式裝置
    • 起搏器
    • 植入式心臟復律去顫器
    • 人工耳蝸
    • 脊髓刺激器
    • 深部腦部刺激器
    • 迷走神經刺激器
    • 薦神經刺激器
  • 非侵入式設備

第6章：按應用

  • 心律不整
  • 感音神經性聽損
  • 癲癇
  • 帕金森氏症
  • 其他

第 7 章：按最終用戶

  • 醫院
  • 門診手術中心
  • 其他

第8章：區域市場分析與成長機會

  • 北美洲
    • 關鍵區域特定動態
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 關鍵區域特定動態
      • 德國
      • 英國
      • 法國
      • 西班牙
      • 義大利
      • 歐洲其他地區
  • 拉丁美洲
    • 關鍵區域特定動態
      • 巴西
      • 阿根廷
      • 拉丁美洲其他地區
  • 亞太
    • 關鍵區域特定動態
      • 中國
      • 印度
      • 日本
      • 韓國
      • 亞太其他地區
  • 中東和非洲
    • 關鍵區域特定動態

第9章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第10章：公司簡介

  • Medtronic Plc
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 關鍵進展
      • 併購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT分析
  • Abbott Laboratories
  • Boston Scientific Corporation
  • LivaNova PLC
  • Biotronik SE & Co. KG
  • Nevro Corp.
  • Cochlear Ltd.
  • electroCore, Inc.
  • Axonics, Inc.
  • NeuroPace, Inc.

第 11 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 12 章：附錄

簡介目錄
Product Code: MD9443

The global bioelectric medicine market reached US$ 31.34 billion in 2024 and is expected to reach US$ 235.55 billion by 2033, growing at a CAGR of 22.3% during the forecast period 2025-2033.

Bioelectric medicine, also known as electroceuticals, is a medical science that uses electrical impulses to treat diseases like arrhythmia, epilepsy, Parkinson's, and chronic pain. It involves implantable devices that stimulate specific nerves or tissues, offering innovative alternatives to pharmaceutical treatments in neurology, cardiology, and other therapeutic areas. This technology integrates neuromodulation and bioengineering, enhancing patient outcomes.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Chronic Diseases

The bioelectric medicine market is driven by the increasing prevalence of chronic diseases like cardiovascular disorders, neurological conditions, and chronic pain, as well as the aging population and increasing cases of arrhythmia, epilepsy, and Parkinson's disease, driven by advancements in neuromodulation technology and expanding electroceutical applications. For instance, The International Diabetes Federation reports that in 2021, 536.6 million adults, or 1 in 10 people, were living with diabetes, with the number predicted to rise to 642.8 million by 2030 and 783.7 million by 2045, particularly in low- and middle-income countries, highlighting the urgent need for diabetes care drugs and devices.

Hence, the increasing diabetes prevalence is driving demand for advanced treatment solutions, including bioelectric medicine. Bioelectric therapies, like neuromodulation devices, offer promising alternatives for managing complications and improving patient outcomes, especially in low- and middle-income countries.

Risk of Device-Related Complications

The bioelectric medicine market faces challenges due to potential device-related complications like infections, malfunctions, and immune responses. Implantable bioelectric devices require surgical procedures, posing risks of post-operative infections, electrode displacement, and hardware failure. Long-term use may require device replacements, increasing healthcare costs and patient concerns, potentially limiting bioelectric medicine's widespread adoption.

Segment Analysis

The global bioelectric medicine market is segmented based on product type, application, end-user and region.

Product Type:

The implantable devices from the product type segment are expected to dominate the bioelectric medicine market with the highest market share

Implantable devices are medical instruments that are surgically placed inside the body to deliver targeted electrical stimulation for therapeutic purposes. They, including pacemakers, ICDs, deep brain stimulators, spinal cord stimulators, and vagus nerve stimulators, work by modulating neural or muscular activity to restore normal physiological functions. They are widely used in treating cardiovascular, neurological, and chronic pain conditions, offering long-term solutions with minimal reliance on pharmaceuticals.

The implantable devices segment is driven by the rise in chronic diseases, particularly cardiovascular and neurological disorders. Technological advancements like miniaturization, wireless connectivity, and rechargeable battery systems are enhancing device efficiency and patient convenience. Growing geriatric populations, expanding healthcare infrastructure, and increased awareness about neuromodulation therapies further boost market growth. Favorable reimbursement policies and research investments contribute to this growth.

For instance, in October 2024, a Carnegie Mellon University-led team was awarded up to $42 billion by ARPA-H to develop implantable, cell-based bioelectric devices for real-time disease monitoring and patient-specific therapy. This is part of the ARPA-H REACT program, which aims to improve chronic disease management through implantable bioelectronic devices.

Geographical Analysis

North America is expected to hold a significant position in the bioelectric medicine market with the highest market share

North America leads the global bioelectric medicine market due to product launches, advanced healthcare infrastructure, innovative medical technologies, and key market players. The region's high prevalence of chronic diseases, favorable reimbursement policies, and investments in neuromodulation research drive demand for implantable bioelectric devices like pacemakers and neurostimulators. Additionally, rising healthcare expenditure and growing awareness of electroceutical therapies contribute to the expanding use of bioelectric medicine in North America.

For instance, in June 2024, electroCore, Inc., a bioelectronic medicine and wellness company, announced the Commercial Off the Shelf (COTS) availability of the next generation TAC-STIM, a non-invasive vagus nerve stimulator designed in partnership with the US military for active-duty military use.

Competitive Landscape

The major global players in the bioelectric medicine market include Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, Biotronik SE & Co. KG, Nevro Corp., Cochlear Ltd, electroCore, Inc., Axonics, Inc., and NeuroPace, Inc., among others.

Key Developments

  • In July 2023, Boston Scientific Corporation received FDA approval for its Vercise Neural Navigator 5 software, which is designed to be used alongside Vercise Genus deep brain stimulation systems. This software offers clinicians practical data for treating Parkinson's disease or essential tremor, allowing them to efficiently program the DBS system.

Why Purchase the Report?

  • Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global bioelectric medicine market report delivers a detailed analysis with 62 key tables, more than 53 visually impactful figures and 165 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Increasing Prevalence of Chronic Diseases
      • 3.1.1.2. Rise in Technological Advancements
    • 3.1.2. Restraints
      • 3.1.2.1. Risk of Device-Related Complications
      • 3.1.2.2. Stringent Regulatory Requirements and Approval Delays
    • 3.1.3. Opportunity
      • 3.1.3.1. Rise in Investment in Research and Development
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with the largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Implantable Devices*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Pacemakers
    • 5.2.4. ICDs
    • 5.2.5. Cochlear Implants
    • 5.2.6. Spinal Cord Stimulators
    • 5.2.7. Deep Brain Stimulators
    • 5.2.8. Vagus Nerve Stimulators
    • 5.2.9. Sacral Nerve Stimulatord
  • 5.3. Non-Invasive Devices

6. By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Arrhythmia*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Sensorineural Hearing Loss
  • 6.4. Epilepsy
  • 6.5. Parkinson's Disease
  • 6.6. Others

7. By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Ambulatory Surgical Centers
  • 7.4. Others

8. Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. Latin America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of Latin America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Medtronic Plc*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Abbott Laboratories
  • 10.3. Boston Scientific Corporation
  • 10.4. LivaNova PLC
  • 10.5. Biotronik SE & Co. KG
  • 10.6. Nevro Corp.
  • 10.7. Cochlear Ltd.
  • 10.8. electroCore, Inc.
  • 10.9. Axonics, Inc.
  • 10.10. NeuroPace, Inc.

LIST NOT EXHAUSTIVE

11. Assumptions and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us